Barclays’s Guardant Health GH Stock Holding History

Barclays’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-45,500	Closed	-$1.31M	–	5355
2024 Q2	$1.31M	Buy	+45,500	New	+$1.06M	﹤0.01%	2429
2022 Q1	–	Sell	-30,000	Closed	-$3M	–	5194
2021 Q4	$3M	Hold	30,000	–	–	﹤0.01%	2095
2021 Q3	$3.75M	Hold	30,000	–	–	﹤0.01%	1825
2021 Q2	$3.73M	Hold	30,000	–	–	﹤0.01%	1771
2021 Q1	$4.58M	Buy	+30,000	New	+$4.53M	﹤0.01%	1589
2019 Q3	–	Sell	-112,500	Closed	-$9.71M	–	6843
2019 Q2	$9.71M	Sell	112,500 -2,500	-2%	-$191K	0.01%	1374
2019 Q1	$8.82M	Buy	+115,000	New	+$6.38M	0.01%	1303

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Barclays's GH Position: Q2 2026 in Review

Barclays reduced its Guardant Health (GH) stake by 40% in Q2 2026, selling an estimated $11.2M and leaving 151,204 shares worth $22.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1067.

Barclays first reported a position in GH in Q4 2018 and has held it in 31 quarters since. The position peaked at $34.3M in Q4 2025. 600 funds tracked by Wall St. Rank hold GH as of Q2 2026.

Barclays held 151,204 shares of Guardant Health worth $22.7M as of Q2 2026.
Barclays sold 102,755 Guardant Health shares in Q2 2026, an estimated $11.2M.
Guardant Health made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1067 holding.
Barclays first reported a position in Guardant Health in Q4 2018 and has held it in 31 quarters since.
Barclays's Guardant Health position peaked at $34.3M in Q4 2025.
600 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.